• Haoran Qin, Qiang Xiao, Yufen Xie, Dan Li, Xiaozhou Long, Taiping Li, Siqing Yi, Yiqin Liu, Jian Chen, and Foyan Xu.
• General Surgery Department, First Affiliated Hospital of Nanchang University, Nanchang, China.
• Medicine (Baltimore). 2023 Jun 30; 102 (26): e34089e34089.

BackgroundExtensive studies on the link between single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGF) and various malignancy risks produced conflicting results, notably for VEGF-460(T/C). To evaluate this correlation more comprehensively and accurately, we perform a meta-analysis.MethodsThrough retrieving 5 databases (Web of Science (WoS), Embase, Pubmed, Wanfang database (Wangfang), and China National Knowledge Infrastructure (CNKI)) and applying hand search, citation search, and gray literature search, 44 papers included 46 reports were enrolled. To evaluate the relationship between VEGF-460 and cancer risk, we pooled odds ratios (ORs) and 95% confidence intervals (CIs).ResultsOur results indicated that the VEGF-460 polymorphism is not related to malignancy susceptibility (dominant model, OR = 0.98, 95% CI = 0.87-1.09; recessive model, OR = 0.95, 95% CI = 0.82-1.10; heterozygous model, OR = 0.99, 95% CI = 0.90-1.10; homozygous model, OR = 0.92, 95% CI = 0.76-1.10; additive model, OR = 0.98, 95% CI = 0.90-1.07). While, in subgroup analysis, this SNP may reduce the risk of hepatocellular carcinoma.Conclusionthis meta-analysis indicated that VEGF-460 was irrelevant to overall malignancy risk, but it might be a protective factor for hepatocellular carcinoma.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

17 keywords...

hide…